GlassScriptPhysician profile
Mohammed N Ibrahim
NPI 1184019143
$8,065.09
in general payments reported to CMS, 2019-2025
27 companies · $759 in 2025
The $759 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $106 · 2021: $1,626 · 2022: $860 · 2023: $1,544 · 2024: $3,170 · 2025: $759.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,202 · Travel and Lodging: $1,272.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,201.74 |
| Travel and Lodging | $1,271.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,882.81 | 2021-2024 | Onyx Frontier, Corevalve Evolut R, Venaseal |
| Abbott Laboratories | $1,358.15 | 2021-2024 | Xience Skypoint, Ultreon, Cardiomems |
| Novartis Pharmaceuticals Corporation | $709.16 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $645.09 | 2020-2025 | Farxiga |
| Pfizer INC. | $571.14 | 2022-2025 | |
| Amgen INC. | $542.69 | 2021-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $478.67 | 2022-2025 | Camzyos, Eliquis |
| Cardiovascular Systems INC. | $241.59 | 2021-2023 | Diamondback Coronary |
| Kiniksa Pharmaceuticals International, Plc | $234.39 | 2024 | Arcalyst |
| Janssen Pharmaceuticals, INC | $199.48 | 2022-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $175.64 | 2022-2025 | Lifevest |
| Alnylam Pharmaceuticals INC. | $161.75 | 2023-2025 | Onpattro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.58 | 2022-2023 | Jardiance |
| Cardiva Medical, INC. | $111.95 | 2023 | Cardiva Vascade 6/7f Vcs |
| Eisai INC. | $104.27 | 2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $89.81 | 2022-2024 | |
| Inari Medical, INC. | $71.23 | 2021 | |
| Abiomed | $67.26 | 2024-2025 | Impella |
| Kiniksa Pharmaceuticals, LTD. | $52.76 | 2023 | Arcalyst |
| Novo Nordisk INC | $43.61 | 2023 | Ozempic |
| Lilly USA, LLC | $40.83 | 2025 | Zepbound |
| Scpharmaceuticals INC. | $33.65 | 2025 | |
| Boston Scientific Corporation | $28.19 | 2023 | |
| Merck Sharp & Dohme LLC | $27.29 | 2022 | |
| Azurity Pharmaceuticals, INC. | $23.02 | 2025 | Edarbi |
| Lexicon Pharmaceuticals, INC. | $22.71 | 2023 | Inpefa |
| Glaxosmithkline, LLC. | $22.37 | 2023 | Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammed Ibrahim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.